Polyclonal Antibody to Macrophage Inflammatory Protein 3 Beta (MIP3b)
| Code | Size | Price |
|---|
| PAA096Mu02-20ul | 20ul | £82.00 |
Quantity:
| PAA096Mu02-100ul | 100ul | £152.00 |
Quantity:
| PAA096Mu02-200ul | 200ul | £204.00 |
Quantity:
| PAA096Mu02-1ml | 1ml | £464.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Mouse
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
CCL19; CKb11; ELC; MIP3-B; SCYA19; Chemokine C-C-Motif Ligand 19; Beta Chemokine Exodus-3; CK Beta-11; EBI1-Ligand Chemokine; Small Inducible Cytokine Subfamily A19
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
Macrophage Inflammatory Protein 3 Beta
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL;
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Macrophage Inflammatory Protein 3 Beta (MIP3b) | RPA096Mu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||